Questions Remain: Giredestrant, Oral SERDs for Breast Cancer

Questions Remain: Giredestrant, Oral SERDs for Breast Cancer

December 21, 2025 Dr. Jennifer Chen Health

Here’s a breakdown of the provided text, summarizing the key data:

Main Topic: Giredestrant in Early-Stage Breast ⁢Cancer

Key Points:

* ⁣ lidERA Trial: A phase 3 trial compared giredestrant (an oral selective estrogen receptor degrader) to standard chemotherapy in patients with early-stage, hormone receptor-positive, HER2-negative breast ⁤cancer.
*⁣ Future Research: Dr. Nora ⁢Teplinsky anticipates further evolution in treatment approaches as results from other SERD (Selective Estrogen Receptor Degrader) trials​ become available.
* Expert Opinion: Dr. ⁣Teplinsky believes how endocrine therapy is used​ for early-stage breast cancer ⁢will change as more research emerges.

Source:

* Healio Interviews (Published by HemOnc Today)

Disclosures:

* Healio was unable to confirm relevant financial disclosures for Dr. Teplinsky at the time of publication.

Additional information:

* ⁣ The​ article includes a promotional section for “Healio AI,” a tool that provides access to clinical information from sources like PubMed, trials, guidelines, and Healio’s news coverage.